<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01596816</url>
  </required_header>
  <id_info>
    <org_study_id>CKNO-PRO-0901</org_study_id>
    <secondary_id>2010-A00237-32</secondary_id>
    <nct_id>NCT01596816</nct_id>
  </id_info>
  <brief_title>Hypofractionated Stereotactic Boost in Prostate Cancer</brief_title>
  <acronym>CKNO-PRO</acronym>
  <official_title>Intermediate-risk Prostate Cancer : Assessment of Hypofractionated Stereotactic Boost - Prospective Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      hypofractionated stereotactic boost radiation (prostate) after normofractionated radiotherapy
      (prostate + seminal vesicles).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to assess the safety of hypofractionated stereotactic boost
      radiation (prostate) after normofractionated radiotherapy (prostate + seminal vesicles).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in rectal functions</measure>
    <time_frame>Every 3 months after boost irradiation during 1 year and then every 6 months during 2 years</time_frame>
    <description>Assessment of rectal toxicity according to the NCI-CTCAE v4.0 scale.
Acute toxicities are defined as all toxicities occurring within 6 months after the start of radiotherapy, late toxicities are those that occur beyond this period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in urinary function.</measure>
    <time_frame>Every 3 months after boost irradiation during 1 year and then every 6 months during 2 years</time_frame>
    <description>Assessment of urinary toxicity according to the NCI-CTCAE v4.0 scale.
Acute toxicities are defined as all toxicities occurring within 6 months after the start of radiotherapy, late toxicities are those that occur beyond this period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local control of prostate cancer</measure>
    <time_frame>3 years</time_frame>
    <description>Local control is defined as:
Non progressive PSA according to Phoenix criteria
Non progressive clinical examination (DRE)
No pathological findings on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global and metastase-free survival</measure>
    <time_frame>Up to 5 years after treatment</time_frame>
    <description>Time measurement between the inclusion and the date of death/metastatic progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA kinetics</measure>
    <time_frame>Between radiotherapy and boost, and after treatment : every 3 months</time_frame>
    <description>Comparison of the PSA dosage before, at the end of treatment then every 3 months. The PSA dosage evolution will be correlate with the local control treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual toxicity</measure>
    <time_frame>Up to 5 years after treatment</time_frame>
    <description>According to IIEF5 questionnaire ( International Index of Erectile Function )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical criteria : Fiducial placement (yes/no)</measure>
    <time_frame>During the time of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary discomfort</measure>
    <time_frame>Up to 5 years after treatment</time_frame>
    <description>According to IPSS questionnaire ( International Prostate Symptom Score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical criteria : Cumulative dosimetry (1 time/ 2 times)</measure>
    <time_frame>During the time of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical criteria : boost schedule (yes/no)</measure>
    <time_frame>During the time of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical criteria : duration of boost</measure>
    <time_frame>During the treatment</time_frame>
    <description>Time between patient's entry and exit of the radiotherapy treatment room</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Boost by CyberKnife</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Boost by linear accelerator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>First part of treatment : Conformal irradiation</intervention_name>
    <description>23 fractions (2 Gy/session), are delivered over 42 days maximum, for a total dose of 46 Gy</description>
    <arm_group_label>Boost by CyberKnife</arm_group_label>
    <arm_group_label>Boost by linear accelerator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fiducials placement</intervention_name>
    <description>Placement of intra-prostatic markers for the tracking</description>
    <arm_group_label>Boost by CyberKnife</arm_group_label>
    <arm_group_label>Boost by linear accelerator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Second part : hypofractionated stereotactic boost</intervention_name>
    <description>3 fractions (6Gy/session) are delivered over 5 to 9 days (at least 48 hours between sessions) for a total dose of 18 Gy</description>
    <arm_group_label>Boost by CyberKnife</arm_group_label>
    <arm_group_label>Boost by linear accelerator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prostate adenocarcinoma proved by histology

          -  With at least one of this intermediate-risk criterias:

               -  T2b

               -  and/or PSA between 10 et 20 ng/ml

               -  and/or Gleason score = 7

          -  Prostatic volume ≤ 80 cc

          -  No adenopathy(lymph node &lt; 1.5 cm on scanner or MRI and/or in lymph node dissection)

          -  No metastasis (bone scan)

          -  Age &gt;= 18 ans

          -  No prior pelvic irradiation

          -  No prior anticancer treatment (prostatectomy, chemotherapy, hormonotherapy &gt; 3 months)

          -  Performance status (ECOG) &lt; 1

          -  No contraindication of fiducials implantation, hemostasis disorders must be treated
             before the implantation

          -  Life expectancy &gt;= 10 weeks

          -  Patient affiliated to health insurance

          -  Informed consent signed by the patient

        Exclusion Criteria:

          -  Cancer no histologically proved

          -  Unfavorable-risk(T2c and/or PSA &gt; 20 ng/ml and/or Gleason &gt; 7)

          -  Favorable-risk(T1c T2a and PSA &lt; 10 ng/ml and Gleason &lt; 7)

          -  T3 and T4

          -  History of cancer uncontrolled and/or treated since less of 5 years (except basal cell
             carcinoma of the skin)

          -  Contraindication to MRI

          -  IPSS score &gt; 10

          -  Recurrent or metastatic disease

          -  Allergy to gold

          -  Patient already included in another therapeutic trial with an experimental molecule

          -  Unable for medical follow-up (geographic, social or mental reasons)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric LARTIGAU, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar LAMBRET</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Val d'Aurelle-Paul Lamarque</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2011</study_first_submitted>
  <study_first_submitted_qc>May 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2012</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

